Drug Trial Radar · NCT01285466
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Last checked: Nov 19, 2026Latest source record: Dec 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
Jan 2011
Primary completion
Oct 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to determine the maximum tolerated dose (MTD) of BEZ235 and BKM120 in combination with weekly paclitaxel and weekly paclitaxel/trastuzumab.
Conditions
- Metastatic or Locally Advanced Solid Tumors
Interventions
BEZ235 + paclitaxelDrug
BKM120 + paclitaxelDrug
BEZ235 + paclitaxel + trastuzumabDrug
BKM120 + paclitaxel + trastuzumabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose limiting toxicities during the first cycle of treatment.Time frame: First treatment cycle (4 weeks)
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Seville, Andalusia, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Chur, Switzerland
Novartis Investigative Site
Sankt Gallen, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.